Drug Profile
Research programme: inflammation therapeutics - Astellas Pharma/ECI
Alternative Names: FROUNT; FROUNT inhibitorLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Effector Cell Institute
- Developer Astellas Pharma; Effector Cell Institute
- Class
- Mechanism of Action Protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammation in Japan